Clinical Study Of The Bionode System In Subjects With Elevated IOP

Inclusion Criteria: 1. Subject ability and willingness to read, comprehend and signed the informed consent form. 2. Subject willingness to comply with study instructions, agreement to make all office appointments, and complete the entire course of the study. 3. Clinical diagnosis of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) with IOP \> 22 mmHg. 4. Subjects \> 22 years of age at the time of the screening examination. 5. Central corneal thickness of \> 450 µm and \< 650 µm in study eye 6. Best-corrected visual acuity (BCVA) or pinhole visual acuity (Snellen) of 20/100 or better in study eye. 7. Subjects with an angle of grade 2 or above via the Shaffer grading system Exclusion Criteria: 1. Angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye 2. Corneal endothelial dysfunction or abnormalities (e.g., Fuchs' Corneal Dystrophy) in either eye 3. Known sensitivity to any products (e.g., contact lens) required for the study procedures 4. A vertical cup to disc ratio of \> 0.8, or notched optic nerve head rim in either eye 5. Visual defect within 10 degrees of fixation or mean deviation of worse than -10 dB 6. History of complications, trauma or disease in the nasolacrimal area. 7. Structural lid abnormalities (i.e., ectropion, entropion) in study eye 8. Active lid disease in either eye (i.e., moderate or severe blepharitis, Meibomian gland dysfunction) that requires medical treatment 9. History of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye 10. Any ophthalmic surgical procedures (i.e., glaucoma laser, minimally invasive glaucoma surgery, refractive, etc.) in study eye within the last six months or will require ophthalmic surgery before completing study 11. History of penetrating keratoplasty in study eye 12. Use of a contact lens in either eye at any time during the study period 13. Uncontrolled diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye 14. Any systemic medication \[i.e., beta-blocker, carbonic anhydrase inhibitors, corticosteroids (including dermal), etc.\], that may have an effect on the subject's IOP, or who will require its use during the study period (Note: an inhaled steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months) 15. Women who are pregnant or lactating. 16. Severe dry eyes. 17. LASIK surgery. 18. Subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study 19. Subject who cannot be successfully fitted with Bionode spectacles and wear contact lenses (if applicable) at the Baseline Visit (day 0)